Back to News
Market Impact: 0.2
Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
Source: GlobeNewswire
Healthcare & BiotechTechnology & Innovation
Myriad announced a collaboration to advance its prostate cancer-specific genomic instability score (PrGIS) technology for precision oncology and companion diagnostics (CDx). The announcement provides no financial terms, timeline, or clinical results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
MYGN0.50
More News
- Verizon stock heads for worst day since 2002 as SpaceX U.S. network plans whack telcos
- Israel’s economy prospers despite years of war, but prices worry voters
- SpaceX’s Wireless Threat Rises With Spectrum Deal
- SpaceX to buy key spectrum that could help Starlink Mobile become major US cell carrier
- Why is T-Mobile stock tumbling today?
- What's behind the recovery rally in tech stocks — plus, Elon Musk's very good week